Archives of Obesity and Metabolism (비만대사연구학술지)

The Study of Obesity and Metabolic Syndrome, KAFM (대한가정의학회 비만대사증후군연구회)
권호 표지
DOI QR코드

DOI QR Code

Weight Reduction Management of Patients with Idiopathic Intracranial Hypertension: A Case Series Report

특발성 두개내 고혈압 환자에서 체중 감량을 동반한 치료 증례 시리즈

  • Jung Ah Lee (Department of Family Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Yongho Lee (Department of Family Medicine, Wonkwang University Sanbon Hospital, Wonkwang University School of Medicine) ;
  • Hye Soon Park (Department of Family Medicine, Asan Medical Center, University of Ulsan College of Medicine)
  • 이정아 (울산대학교 의과대학 서울아산병원 가정의학과) ;
  • 이용호 (원광대학교 의과대학 원광대학교 산본병원 가정의학과) ;
  • 박혜순 (울산대학교 의과대학 서울아산병원 가정의학과)
  • Received : 2024.04.02
  • Accepted : 2024.06.15
  • Published : 2024.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Idiopathic intracranial hypertension (IIH) is characterized by increased intracranial pressure without detectable causes. Its main symptoms include headache, vision problems, and pulsatile tinnitus. Obesity is a major risk factor for IIH; therefore, weight reduction is required to ameliorate these symptoms in patients with obesity and IIH. We present four cases of obesity-related IIH whose symptoms improved through weight reduction. In three patients, the dose of IIH medications, such as acetazolamide, decreased. Based on these cases, we report that weight reduction contributes to the improvement of symptoms in patients with IIH as the main part of treatment. Further clinical research is necessary to evaluate the effects of weight reduction on IIH treatment in Korean patients.

Keywords

References

  1. Friesner D, Rosenman R, Lobb BM, Tanne E. Idiopathic intracranial hypertension in the USA: the role of obesity in establishing prevalence and healthcare costs. Obes Rev 2011;12:e372-80. 
  2. Jensen RH, Radojicic A, Yri H. The diagnosis and management of idiopathic intracranial hypertension and the associated headache. Ther Adv Neurol Disord 2016;9:317-26. 
  3. Markey KA, Mollan SP, Jensen RH, Sinclair AJ. Understanding idiopathic intracranial hypertension: mechanisms, management, and future directions. Lancet Neurol 2016;15:78-91. 
  4. Kesler A, Goldhammer Y, Gadoth N. Do men with pseudomotor cerebri share the same characteristics as women? A retrospective review of 141 cases. J Neuroophthalmol 2001;21:15-7. 
  5. Mollan SP, Davies B, Silver NC, Shaw S, Mallucci CL, Wakerley BR, et al. Idiopathic intracranial hypertension: consensus guidelines on management. J Neurol Neurosurg Psychiatry 2018;89:1088-100. 
  6. Wang MTM, Bhatti MT, Danesh-Meyer HV. Idiopathic intracranial hypertension: pathophysiology, diagnosis and management. J Clin Neurosci 2022;95:172-9. 
  7. Kilgore KP, Lee MS, Leavitt JA, et al. Re-evaluating the incidence of idiopathic intracranial hypertension in an era of increasing obesity. Ophthalmology 2017;124:697-700. 
  8. Miah L, Strafford H, Fonferko-Shadrach B, et al. Incidence, prevalence, and health care outcomes in idiopathic intracranial hypertension: a population study. Neurology 2021;96:e1251-61. 
  9. Kesler A, Kliper E, Shenkerman G, Stern N. Idiopathic intracranial hypertension is associated with lower body adiposity. Ophthalmology 2010;117:169-74. 
  10. Hornby C, Mollan SP, Botfield H, O'Reilly MW, Sinclair AJ. Metabolic concepts in idiopathic intracranial hypertension and their potential for therapeutic intervention. J Neuroophthalmol 2018;38:522-30. 
  11. Andrews LE, Liu GT, Ko MW. Idiopathic intracranial hypertension and obesity. Horm Res Paediatr 2014;81:217-25. 
  12. Kim TW, Choung HK, Khwarg SI, Hwang JM, Yang HJ. Obesity may not be a risk factor for idiopathic intracranial hypertension in Asians. Eur J Neurol 2008;15:876-9. 
  13. World Health Organization (WHO). The Asia-Pacific perspective: redefining obesity and its treatment. Geneva: WHO; 2000. 
  14. Haam JH, Kim BT, Kim EM, et al. Diagnosis of obesity: 2022 update of clinical practice guidelines for obesity by the Korean Society for the Study of Obesity. J Obes Metab Syndr 2023;32:121-9. 
  15. Gafoor VA, Smita B, Jose J. Obesity, ethnicity and idiopathic intracranial hypertension. Ann Indian Acad Neurol 2019;22:352. 
  16. Sinclair AJ, Burdon MA, Nightingale PG, et al. Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study. BMJ 2010;341:c2701. 
  17. Krajnc N, Itariu B, Macher S, et al. Treatment with GLP-1 receptor agonists is associated with significant weight loss and favorable headache outcomes in idiopathic intracranial hypertension. J Headache Pain 2023;24:89. 
  18. Mollan SP, Mitchell JL, Ottridge RS, et al. Effectiveness of bariatric surgery vs community weight management intervention for the treatment of idiopathic intracranial hypertension: a randomized clinical trial. JAMA Neurol 2021;78:678-86. 
  19. Wall M, McDermott MP, Kieburtz KD, et al. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. JAMA 2014;311:1641-51. 
  20. Ko MW, Chang SC, Ridha MA, et al. Weight gain and recurrence in idiopathic intracranial hypertension: a case-control study. Neurology 2011;76:1564-7. 
  21. Daniels AB, Liu GT, Volpe NJ, et al. Profiles of obesity, weight gain, and quality of life in idiopathic intracranial hypertension (pseudotumor cerebri). Am J Ophthalmol 2007;143:635-41. 
  22. Johnson LN, Krohel GB, Madsen RW, March GA Jr. The role of weight loss and acetazolamide in the treatment of idiopathic intracranial hypertension (pseudotumor cerebri). Ophthalmology 1998;105:2313-7. 
  23. Nam GE, Kim YH, Han K, Jung JH, Rhee EJ, Lee WY. Obesity fact sheet in Korea, 2020: prevalence of obesity by obesity class from 2009 to 2018. J Obes Metab Syndr 2021;30:141-8. 
  24. Nam GE, Kim YH, Han K, et al. Obesity fact sheet in Korea, 2019: prevalence of obesity and abdominal obesity from 2009 to 2018 and social factors. J Obes Metab Syndr 2020;29:124-32. 
  25. Huh Y, Kim SH, Nam GE, Park HS. Weight gain, comorbidities, and its associated factors among Korean adults. J Korean Med Sci 2023;38:e90.